Free tool
FAERS Monitor: Fetroja
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209445 or its brand name (Fetroja, Cefiderocol Sulfate Tosylate). Reports on generic versions are filed under their own applications.
Reports
315
Serious
282
90% of reports
Hospitalization
68
Death reported
147
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death71
- drug resistance31
- treatment failure27
- off label use26
- acute kidney injury23
- pathogen resistance17
- hepatic cytolysis14
- multiple organ dysfunction syndrome14
- infection13
- cholestasis12
- condition aggravated11
- septic shock11
- encephalopathy10
- no adverse event10
- chromaturia9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 11 |
| 2021 | 32 |
| 2022 | 71 |
| 2023 | 82 |
| 2024 | 68 |
| 2025 | 33 |
| 2026 | 18 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,844 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pathogen resistanceSignal | 17 | 124.8 | 78.5 | 1,962 |
| drug resistanceSignal | 31 | 80.7 | 57.7 | 2,360 |
| hepatic cytolysisSignal | 14 | 73.4 | 44.0 | 928 |
| cholestasisSignal | 12 | 41.8 | 24.0 | 438 |
| multiple organ dysfunction syndromeSignal | 14 | 33.0 | 19.8 | 404 |
| encephalopathySignal | 10 | 27.2 | 14.8 | 227 |
| chromaturiaSignal | 9 | 26.6 | 14.0 | 197 |
| treatment failureSignal | 27 | 21.8 | 15.2 | 516 |
| septic shockSignal | 11 | 16.9 | 9.4 | 149 |
| acute kidney injurySignal | 23 | 10.0 | 6.8 | 179 |
| infectionSignal | 13 | 6.0 | 3.5 | 50 |
| deathSignal | 71 | 5.5 | 4.5 | 268 |
| no adverse eventSignal | 10 | 3.7 | 2.0 | 17 |
| condition aggravatedSignal | 11 | 2.4 | 1.4 | 8 |
| off label use | 26 | 2.0 | 1.4 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.